Table 1. Baseline characteristics of HIV-infected and uninfected women in WIHS.
| HIV+ (N = 908) |
Control (N = 289) |
P Value | |
|---|---|---|---|
| Age (y) | 41 (36-46) | 40 (34-45) | 0.0086 |
| <30 | 55 (6%) | 38 (13%) | |
| 30-40 | 350 (39%) | 109 (38%) | |
| 40-50 | 410 (45%) | 111 (38%) | |
| >50 | 93 (10%) | 31 (11%) | |
| Race | 0.0058 | ||
| African American | 524 (58%) | 178 (62%) | |
| Caucasian | 175 (19%) | 33 (11%) | |
| Other | 209 (23%) | 78 (27%) | |
| Cigarette Smoking | 0.071 | ||
| Current | 464 (51%) | 170 (59%) | |
| Past | 224 (25%) | 62 (21%) | |
| Never | 220 (24%) | 57 (20%) | |
| Diabetes Mellitus | 86 (9%) | 26 (9%) | 0.91 |
| Hypertension | 228 (25%) | 80 (28%) | 0.40 |
| Antihypertensive Use | 98 (11%) | 35 (12%) | 0.52 |
| Menopause | 185 (21%) | 40 (14%) | 0.0076 |
| Hepatitis C | 281 (31%) | 62 (22%) | 0.0021 |
| LDL (mg/dL) | 103 (80-132) | 104 (86-129) | 0.30 |
| HDL (mg/dL) | 44 (36-56) | 51 (42-62) | <0.0001 |
| TG (mg/dL) | 133 (93-196) | 101 (73-150) | <0.0001 |
| Body Mass Index (kg/m2) | 27 (23-31) | 29 (24-34) | <0.0001 |
| Waist Circumference (cm) | 88 (80-99) | 93 (80-104) | 0.0064 |
| Current Heroin Use | 43 (5%) | 23 (8%) | 0.053 |
| Current HAART Use | 533 (59%) | ||
| Current NRTI Use | 606 (67%) | ||
| Current NNRTI Use | 246 (27%) | ||
| Current PI Use | 381 (42%) | ||
| Current CD4 Count (cells/mm3) | 397 (245-576) | ||
| Nadir CD4 Count (cells/mm3) | 212 (109-326) | ||
| History of AIDS | 445 (49%) | ||
| HIV Viral Load (copies/mL) | |||
| ≤80 | 276 (31%) | ||
| 81-1999 | 204 (23%) | ||
| 2000-9999 | 147 (16%) | ||
| >10000 | 275 (30%) | ||
| eGFR Cys <60ml/min/1.73m2 | 84 (9%) | 6 (2%) | <.0001 |
| eGFR Cr <60ml/min/1.73m2 | 64 (7%) | 14 (5%) | 0.22 |
Data are presented as Median (IQR) or numbers (percent).
Abbreviations: IQR, interquartile range; HAART, highly active antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor